Asunto(s)
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Guías como Asunto , Agencias Internacionales/organización & administración , Farmacovigilancia , Organización Mundial de la Salud/organización & administración , Humanos , Cooperación Internacional , Medición de RiesgoRESUMEN
INTRODUCTION: Technical and logical breakthroughs have provided new opportunities in medicine to use knowledge bases and large-scale clinical data (real-world) at point-of-care as part of a learning healthcare system to diminish the knowledge-practice gap. AREAS COVERED: The article is based on presentations, discussions and recommendations from an international scientific workshop. Value, research needs and funding avenues of knowledge bases and access to real-world data as well as transparency and incorporation of patient perspectives are discussed. EXPERT OPINION: Evidence-based, publicly funded, well-structured and curated knowledge bases are of global importance. They ought to be considered as a public responsibility requiring transparency and handling of conflicts of interest. Information has to be made accessible for clinical decision support systems (CDSS) for healthcare staff and patients. Access to rich and real-world data is essential for a learning health care ecosystem and can be augmented by data on patient-reported outcomes and preferences. This field can progress by the establishment of an international policy group for developing a best practice guideline on the development, maintenance, governance, evaluation principles and financing of open-source knowledge bases and handling of real-world data.
Asunto(s)
Sistemas de Apoyo a Decisiones Clínicas , Atención a la Salud/organización & administración , Medicina Basada en la Evidencia/normas , Bases del Conocimiento , Atención a la Salud/normas , Humanos , Internacionalidad , Medición de Resultados Informados por el Paciente , Guías de Práctica Clínica como AsuntoRESUMEN
PURPOSE: The symposium Health and Medicines in Indigenous Populations of America was organized by the Council for International Organizations of Medical Sciences (CIOMS) Working Group on Clinical Research in Resource-Limited Settings (RLSs) and the Ibero-American Network of Pharmacogenetics and Pharmacogenomics (RIBEF). It was aimed to share and evaluate investigators' experiences on challenges and opportunities on clinical research and pharmacogenetics. METHODS: A total of 33 members from 22 countries participated in 2 sessions: RIBEF studies on population pharmacogenetics about the relationship between ancestry with relevant drug-related genetic polymorphisms and the relationship between genotype and phenotype in Native Americans (session 1) and case examples of clinical studies in RLSs from Asia (cancer), America (diabetes and women health), and Africa (malaria) in which the participants were asked to answer in free text their experiences on challenges and opportunities to solve the problems (session 2). Later, a discourse analysis grouping common themes by affinity was conducted. FINDINGS: The main result of session 1 was that the pharmacogenetics-related ancestry of the population should be considered when designing clinical studies in RLSs. In session 2, 21 challenges and 20 opportunities were identified. The social aspects represent the largest proportion of the challenges (43%) and opportunities (55%), and some of them seem to be common. IMPLICATIONS: The main discussion points were gathered in the Declaration of Mérida/T'Hó and announced on the Parliament of Extremadura during the CIOMS-RIBEF meeting in 4 of the major Latin American autochthonous languages (Náhualth, Mayan, Miskito, and Kichwa). The declaration highlighted the following: (1) the relevance of population pharmacogenetics, (2) the sociocultural contexts (interaction with traditional medicine), and (3) the education needs of research teams for clinical research in vulnerable and autochthonous populations.
Asunto(s)
Investigación Biomédica , Farmacogenética , África , Asia , Diabetes Mellitus/genética , Genotipo , Recursos en Salud , Humanos , Malaria/genética , Neoplasias/genética , Fenotipo , Polimorfismo Genético , Estados Unidos , Salud de la Mujer , Indio Americano o Nativo de AlaskaRESUMEN
BACKGROUND: In 2018, the Council for International Organizations of Medical Sciences (CIOMS) issued their Guide to Vaccine Safety Communication. This has been built upon existing guidance and a new review of research and compilation of latest experiences, in order to fill, for the first time at global level, a specific niche for regulatory authorities in the contexts of vaccine hesitancy and informed choice. The Guide was developed by the international multi-stakeholder CIOMS Working Group on Vaccine Safety, formed to assist the Global Vaccine Safety Initiative (GVSI) of the World Health Organization (WHO). SUMMARY: Besides the public health authorities responsible for immunization programmes, regulators have their own role in communicating about vaccine safety. As they are responsible for licensing vaccine products, they need to be transparent about their assessments of data on quality, safety and efficacy. Furthermore, they are responsible for continuous safety surveillance and keeping safe use advice to the public up-to-date. The Guide stresses the fundamental importance of regulatory bodies to have a system in place with defined functions and skilled persons who can efficiently run vaccine safety communication in collaboration with stakeholders. This system should take a strategic approach to communication, be integral to safety surveillance and risk assessment, and support vaccine safety communication plans (VacSCPs) adapted to vaccine types in local situations. The Guide provides recommendations and examples for the system components as well as a practical VacSCP template. CONCLUSIONS: While the Guide should help strengthening regulatory bodies worldwide with regard to vaccine safety communication, it is meant to help regulators in resource-limited countries in particular. It can also be of interest to other stakeholders and be leveraged to other medicinal products.
Asunto(s)
Sistemas de Registro de Reacción Adversa a Medicamentos/organización & administración , Comunicación , Congresos como Asunto , Vacunas/administración & dosificación , Organización Mundial de la Salud , Humanos , Farmacovigilancia , Medición de Riesgo , Vacunas/efectos adversosRESUMEN
The quality of medicines is generally adequately assured by manufacturers and regulatory authorities for well-resourced settings, while the implementation of existing quality standards is challenged in many low- and middle-income countries. This situation of multiple pharmaceutical standards raises the question whether it could ever be ethically justified to compromise on the quality assurance of medicines depending on what individuals, communities, or societies can afford. In this paper, we contend that ethically, any unjustified exceptions to medicines' quality assurance represents a violation of the principles of beneficence and non-maleficence. Exceptions are only acceptable in exceptional and temporary circumstances, if based on a meaningful quality risk assessment, guided by a rigorous ethical framework built on the principles of independence, technical competence, transparency, and accountability. We also discuss how such exceptional and temporary circumstances should be defined/justified. Finally, we propose that empirical bioethics should acknowledge the existence of these dilemmas in public health, and help to build a normative approach to dealing with them. Ideally, an international group of experts in quality assurance/regulatory affairs and health ethicists should be set up to take up this topic and formulate a Guide to Ethical Principles of Quality Assurance of Medical Products.
RESUMEN
BACKGROUND: Availability of correct and adequate information about medicines is an important aspect in ensuring rational use of medicines and hence facilitating safety and expected efficacy of medicines during therapy. Package inserts have proven to be a good source of information to the prescribers and patients whereby they have been useful in highlighting important information pertaining proper use and handling of the medicines. The present study was aimed at establishing the extent to which package inserts of medicines circulating on the markets of the East African Community (EAC) Partner States conform to medicines information requirements as established in the harmonized guidelines as well as national guidelines. METHODS: A total of 99 package inserts from six (6) types of medicines namely Albendazole, Artemether/Lumefantrine (ALu), Ciprofloxacin, Paracetamol, Amoxicillin and Metronidazole were purposefully collected from three EAC Partner States: Kenya, Tanzania and Uganda. The medicines were selected based on their indications as first line treatments, high rates of utilization within the medicines supply system and their positions in treatment of diseases of public importance across EAC Partner States. The inserts were evaluated on the availability of information regarding fifteen (15) parameters as extracted from the EAC harmonized guidelines for registration of medicines. Moreover, comparisons were made between the percentage conformity of the branded versus generic products, markets from which the samples were collected, origin of the manufacturer and type of medicine. RESULTS: Majority (93.9-100%) of the medicines' package inserts highly conformed to the inclusion of the information regarding the description and composition of the medications, indications, dosage and methods of administration, warnings and precautions, contraindications and storage conditions. However, the information on handling and disposal, container package description, excipients used, clinical pharmacology of the medicines, and directions regarding overdose ranked the least in conformance with conformity ranging from 13.1-52.5%. The parameter with the lowest observed percentage conformity among the branded products scored 50% as compared to 10.8% among the generic products. Moreover, there was no significant difference (P<0.05) in the percentage conformity of the package inserts collected from each of the three Partner States as compared to the average from studied medicines. A generally good conformity was observed among medicines manufactured by European based manufacturers as compared to those based in Asia and EAC Partner States. In addition, PIs of Albendazole, Ciprofloxacin, Amoxicillin and Artemether/Lumefantrine did show overall high conformity across most of the product information requirements. CONCLUSION: Our study revealed the existence of a significant number of medicinal products circulating on the markets of EAC Partner States without necessary compliance with all product information requirements. We therefore recommend that NMRAs ensure thorough pre-market assessment of product information as well as strengthening their post marketing surveillance to ensure that medicines circulating on the market comply to medicines information requirements at all times. Emphasis should also be given to manufacturers on the importance of inclusion of appropriate and adequate product information for the safety of patients, including advocating for inclusion of patient-friendly and easy to understand medicines information.
Asunto(s)
Etiquetado de Medicamentos/economía , Etiquetado de Medicamentos/legislación & jurisprudencia , Embalaje de Medicamentos/economía , Embalaje de Medicamentos/legislación & jurisprudencia , Medicamentos Genéricos/economía , Mercadotecnía/economía , África OrientalAsunto(s)
Conservación de los Recursos Naturales , Países en Desarrollo , Costos de los Medicamentos , Medicamentos Esenciales/economía , Gastos en Salud , Cobertura Universal del Seguro de Salud , Medicamentos Esenciales/normas , Medicamentos Esenciales/provisión & distribución , Humanos , Organización Mundial de la SaludAsunto(s)
Investigación Biomédica/legislación & jurisprudencia , Brotes de Enfermedades/prevención & control , Descubrimiento de Drogas/legislación & jurisprudencia , Vacunas contra el Virus del Ébola/uso terapéutico , Política de Salud/legislación & jurisprudencia , Fiebre Hemorrágica Ebola/prevención & control , Formulación de Políticas , Salud Pública/legislación & jurisprudencia , Vacunación/legislación & jurisprudencia , Ensayos Clínicos como Asunto/legislación & jurisprudencia , Vacunas contra el Virus del Ébola/efectos adversos , Vacunas contra el Virus del Ébola/inmunología , Urgencias Médicas , Comités de Ética en Investigación/legislación & jurisprudencia , Regulación Gubernamental , Fiebre Hemorrágica Ebola/epidemiología , Fiebre Hemorrágica Ebola/inmunología , Fiebre Hemorrágica Ebola/transmisión , Humanos , Vacunación/efectos adversosRESUMEN
OBJECTIVES: We assessed the characteristics of currently implemented expedited (facilitated) regulatory pathways (FRPs) used by national regulatory authorities (NRAs) in emerging economies to speed access to important new medicines. METHODS: We identified NRAs with FRPs through Thomson Reuters Cortellis Regulatory Intelligence and through agency Websites. We developed a list of 27 FRP characteristics. We categorised characteristics as procedural or substantive and based them on five sequential regulatory activities. FINDINGS: We assessed 29 countries with 33 FRPs. The regions with the characteristics described most extensively by their FRPs were the Middle East/North Africa and Eastern Europe. The Sub-Saharan African region included the FRPs that were least specific in describing characteristics. Overall, FRPs presented at least twice as many procedural as substantive characteristics. CONCLUSIONS: We observed diversity by region in FRP characteristics, suggesting a role for further engagement with emerging NRAs in their design and implementation. Common processes could advance regulatory alignment initiatives and help the WHO inform the development of novel, globally aligned accelerated development and regulatory pathways for products that fulfil serious unmet public health needs.Journal of Public Health Policy advance online publication, 10 March 2016; doi:10.1057/jphp.2016.8.
RESUMEN
Medicines of uncertain quality, safety and efficacy can be worse than no treatment at all. It is the responsibility of national medicines regulatory authorities to protect patients from harm. Yet, there are great disparities in regulatory capacity globally, preventing large populations from accessing the benefits of advances in the pharmaceutical field. This article describes the main regulatory functions and how they are applied to assure the quality, safety and efficacy of different types of medicines in different environments. It gives examples of initiatives that have increased access to good quality medicines worldwide and - more importantly - are laying the groundwork for collaborative approaches aiming to ensure that pharmaceutical products meet the same, stringent quality standards in all parts of the world.
Asunto(s)
Fármacos Anti-VIH/provisión & distribución , Terapia Antirretroviral Altamente Activa , Medicamentos Falsificados/provisión & distribución , Medicamentos Genéricos/provisión & distribución , Infecciones por VIH/tratamiento farmacológico , Fármacos Anti-VIH/economía , Aprobación de Drogas , Medicamentos Genéricos/economía , Guías como Asunto , Humanos , Cooperación Internacional , Política Organizacional , Control de Calidad , Equivalencia Terapéutica , Organización Mundial de la SaludRESUMEN
PURPOSE: The aim of this work was to determine the number and type of active pharmaceutical ingredient (API) quality deficiencies in API Master Files (APIMFs) as submitted to the World Health Organization (WHO) Prequalification of Medicines Programme (PQP). METHODS: We conducted a retrospective review of API quality deficiencies identified following the assessment of new APIMFs for non-sterile APIs during a 6-year period from 1 January 2007 to 31 December 2012. All deficiencies were collected, classified and quantified according to the Common Technical Document (CTD) sections and subsections and as groups of commonly raised questions. RESULTS: There were 5446 deficiencies collected from 159 APIMF deficiency letters by CTD section, by selected CTD subsections and by selected CTD subsections and year. More than 50% of the total number of deficiencies related to the manufacturing sections of the CTD, followed by deficiencies concerning the impurities, the API specification and the stability sections of the CTD. A pattern of API deficiencies across the different CTD subsections and over time was identified. CONCLUSIONS: The most frequent critical deficiencies were related to how the specific manufacturing process and the key materials used, in particular the API starting material, impact the API impurities content. The number and pattern of APIMF deficiencies did not change over time. The results are compared to the findings in similar studies as reported by the United States Food and Drug Administration (USFDA), the European Directorate for the Quality of Medicines (EDQM) and the European Medicines Agency (EMA) and similarities and differences are discussed. Our findings highlight the need for greater guidance and technical assistance for API manufacturers submitting APIMFs to the PQP.
Asunto(s)
Documentación , Preparaciones Farmacéuticas , Organización Mundial de la Salud , Control de CalidadRESUMEN
In 2005, the World Health Organization (WHO) proposed that provided an active pharmaceutical ingredient could meet certain criteria, bioequivalence could be evaluated with a set of laboratory tests, obviating the need for expensive and time-consuming pharmacokinetic studies in humans. The aim of this work was to determine whether this so-called "biowaiver" procedure can be applied to antituberculosis products. Antituberculosis products from the WHO Prequalification Programme, including three ethambutol, two isoniazid and one pyrazinamide product, were investigated. In vitro dissolution data for these products were generated according to the biowaiver method stipulated in the WHO Guidance, and the bioequivalence decision based on these data was compared with that based on the corresponding in vivo pharmacokinetic data. In no case was a "false positive" bioequivalence decision reached using the biowaiver procedure, that is, all products deemed bioequivalent according to the biowaiver methods also proved to be bioequivalent in the corresponding pharmacokinetic study. These findings open the way to a simplified method of ensuring bioequivalence of antituberculosis drug products, thereby improving access to high quality antituberculosis medicines for a greater number of patients.
Asunto(s)
Antituberculosos/química , Antituberculosos/farmacocinética , Aprobación de Drogas , Tuberculosis/tratamiento farmacológico , Organización Mundial de la Salud , Cromatografía Líquida de Alta Presión , Reacciones Falso Positivas , Humanos , Reproducibilidad de los Resultados , Solubilidad , Espectrofotometría , Equivalencia TerapéuticaAsunto(s)
Pediatría , Farmacopeas como Asunto , Organización Mundial de la Salud , Preescolar , HumanosAsunto(s)
Publicidad/ética , Industria Farmacéutica/ética , Publicidad/normas , Anticolesterolemiantes/uso terapéutico , Enfermedades Cardiovasculares/sangre , Enfermedades Cardiovasculares/mortalidad , Enfermedades Cardiovasculares/prevención & control , Colesterol/sangre , Adhesión a Directriz , Humanos , Responsabilidad Social , Organización Mundial de la SaludRESUMEN
This paper outlines the development of a CD-ROM training package entitled: The WHO Basic Training Modules on GMP, intended to support the creation of training courses aimed particularly at government compliance officials who inspect pharmaceutical manufacturing facilities. The material was created over a three-year period in collaboration with a team of external experts, WHO regional and local offices, and Drug Regulatory Authorities of participating countries. The nine training workshops and courses that contributed to the development and evaluation processes were attended by approximately 240 participants from 47 countries. To date over 5,800 copies of the CD-ROM have been distributed.